Fox Chase Cancer Center News

Rates of Confirmatory Prostate Biopsy ‘Surprisingly Low’ With Use of Active Surveillance

PHILADELPHIA (October 1, 2020) – Active surveillance is being increasingly used as a treatment option for men diagnosed with low-risk prostate cancer. A recent study led by researchers at Fox Chase Cancer Center, however, has found that only about 60% of men who choose active surveillance are undergoing guideline-recommended confirmatory biopsy within 12 months of their diagnosis.

VIEW STORY